Posted by Michael Wonder on 17 Feb 2025
Innate Pharma announces US FDA granted breakthrough therapy designation to lacutamab for relapsed or refractory Sézary syndrome
17 February 2025 - Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favourable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab.
Innate Pharma today announced that the US FDA has granted breakthrough therapy designation to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory Sézary syndrome after at least 2 prior systemic therapies including mogamulizumab.
